Drugs / Personalized peptide vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03068832 | Sep 2021 → Mar 2023 | brain cancer | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT02510950 | Dec 2015 → Feb 2017 | glioblastoma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03068832 ↗ |
| Modality | Vaccine | “The synthetic long peptide vaccine platform has an excellent safety profile” NCT03068832 ↗ |